Compare · CHMA vs FLXN
CHMA vs FLXN
Side-by-side comparison of Chiasma, Inc. (CHMA) and Flexion Therapeutics, Inc. (FLXN): market cap, price performance, sector, and recent activity on the wire.
Summary
- Both CHMA and FLXN operate in Major Pharmaceuticals (Health Care), so they compete in similar markets.
- FLXN carries a market cap of $458.9M.
- FLXN has more recent analyst coverage (7 ratings vs 0 for CHMA).
- Company
- Chiasma, Inc.
- Flexion Therapeutics, Inc.
- Price
- $3.76-6.12%
- $25.11-0.20%
- Market cap
- -
- $458.9M
- 1M return
- -
- -0.20%
- 1Y return
- -
- -1.57%
- Industry
- Major Pharmaceuticals
- Major Pharmaceuticals
- Exchange
- NASDAQ
- NASDAQ
- IPO
- 2015
- 2014
- News (4w)
- 0
- 0
- Recent ratings
- 0
- 7
Chiasma, Inc.
Chiasma, Inc., a commercial-stage biopharmaceutical company, focuses on developing and commercializing oral medications using transient permeability enhancer technology platform for the treatment of rare and serious chronic disease worldwide. The company offers MYCAPSSA, an oral octreotide capsule for the long-term maintenance treatment in acromegaly patients who have responded to and tolerated treatment with octreotide or lanreotide. It also develops MPOWERED, an oral octreotide capsule, which has completed Phase III clinical trials for the maintenance treatment of adult patients with acromegaly. Chiasma, Inc. was incorporated in 2001 and is headquartered in Needham, Massachusetts.
Flexion Therapeutics, Inc.
Flexion Therapeutics, Inc., a biopharmaceutical company, focuses on the discovery, development, and commercialization of therapies for the treatment of patients with musculoskeletal conditions in the United States. The company offers ZILRETTA, an intra-articular injection for the management of osteoarthritis (OA) knee pain. It is also involved in the development of FX201, a gene therapy product candidate designed to provide on demand production of an anti-inflammatory protein, interleukin-1 receptor antagonist for pain relief from OA of the knee; and FX301, a NaV1.7 inhibitor for the management of post-operative pain. The company was founded in 2007 and is headquartered in Burlington, Massachusetts.
Latest CHMA
- Amryt Reports Q3 2022 Financial and Operational Results
- Amryt Reports Record Q2 2022 Results
- SpyBiotech Appoints Seasoned Biotech Executive Mark Leuchtenberger as Chief Executive Officer
- Amryt Reports Record Q1 2022 Results
- Amryt Announces 22% growth in FY 2021 Revenues to $222.5M
- SEC Form EFFECT filed by Chiasma, Inc.
- SEC Form 15-12B filed by Chiasma, Inc.
- SEC Form 4: STONEPINE CAPITAL, L.P. returned 6,770,000 units of Common Stock to the company
- SEC Form SC 13G/A filed by Chiasma, Inc. (Amendment)
- SEC Form S-8 POS filed by Chiasma, Inc.
Latest FLXN
- Avilar Therapeutics Appoints Adam Muzikant, PhD, as Chief Business Officer
- SEC Form 15-12B filed by Flexion Therapeutics, Inc.
- SEC Form EFFECT filed by Flexion Therapeutics, Inc.
- SEC Form 4 filed by Newtyn Management, Llc
- SEC Form 3: New insider Newtyn Management, Llc claimed ownership of 5,900,000 shares
- SEC Form 4: Stejbach Mark returned $107,364 worth of shares to the company (12,631 units at $8.50), closing all direct ownership in the company to cover taxes
- SEC Form 4: Milinazzo Alan returned $233,325 worth of shares to the company (27,450 units at $8.50), closing all direct ownership in the company to satisfy withholding tax
- SEC Form 4: Merrifield C Ann returned $161,500 worth of shares to the company (19,000 units at $8.50), closing all direct ownership in the company to cover withholding tax
- SEC Form 4: Lukatch Heath returned $76,500 worth of shares to the company (9,000 units at $8.50), closing all direct ownership in the company to satisfy tax liability
- SEC Form 4: Kwo Elizabeth returned $38,250 worth of shares to the company (4,500 units at $8.50), closing all direct ownership in the company (tax liability)